Search
Pliant Therapeutics Inc
PLRXAdd to Watchlist
1.140USD
+0.030+2.70%
Market hours （ET）Quotes delayed by 15 min
70.58MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.70%
5 Days
+0.88%
1 Month
-5.00%
6 Months
-6.56%
Year to Date
-6.56%
1 Year
-2.56%
Key Figures
1.110Open
1.140High
74.92KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
1.110Prev. Close
1.110Low
28.76KTurnover
LossP/E Static
0.43P/B
0.00%Div Yield TTM
-41.37%ROA
1.95052wk High
1.31Volume Ratio
-210.30MNet Profit
61.91MShares
-1.8405EPS TTM
1.21Beta
-53.62%ROE
1.09052wk Low
2.70%Amplitude
100.00%Gross Margin
70.58MMarket Cap
-1.13Reward/Risk
3.81%Risk Rate
TradingKey Stock Score of Pliant Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Pliant Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pliant Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Pliant Therapeutics Inc Highlights
StrengthsRisks
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Fairly Valued
The company’s latest PE is -0.60, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.65M shares, decreasing 49.04% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 47.81K shares of this stock.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
2.500
Target Price
+119.30%
Upside Space
Pliant Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pliant Therapeutics Inc Info
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Ticker SymbolPLRX
CompanyPliant Therapeutics Inc
CEOCoulie (Bernard J)
Websitehttps://pliantrx.com/
Related Instruments
+2.31%
+1.41%
+4.86%
+2.00%
+1.93%
+3.35%
+2.55%
+3.66%
+2.81%
+1.95%
+3.94%
+1.79%
+3.70%
+3.36%
+1.41%
0.00%
+2.45%
+3.92%
+0.58%
+4.20%Popular Instruments
52719.400
+465.100 (+0.89%)
29691.400
-107.900 (-0.36%)
7512.400
+36.900 (+0.49%)
14840.000
-515.000 (-3.35%)
68864.000
-621.000 (-0.89%)
6373.000
+97.600 (+1.55%)
67.584
-0.384 (-0.56%)
304.850
+10.470 (+3.56%)
198.801
+1.221 (+0.62%)
4117.820
+87.050 (+2.16%)
FAQs
What is the current price of Pliant Therapeutics Inc (PLRX)?
The current price of Pliant Therapeutics Inc (PLRX) is 1.11.
What is the symbol of Pliant Therapeutics Inc?
The ticker symbol of Pliant Therapeutics Inc is PLRX.
What is the 52-week high of Pliant Therapeutics Inc?
The 52-week high of Pliant Therapeutics Inc is 1.95.
What is the 52-week low of Pliant Therapeutics Inc?
The 52-week low of Pliant Therapeutics Inc is 1.09.
What is the market capitalization of Pliant Therapeutics Inc?
The market capitalization of Pliant Therapeutics Inc is 68.73M.
Is Pliant Therapeutics Inc (PLRX) currently rated as Buy, Hold, or Sell?
According to analysts, Pliant Therapeutics Inc (PLRX) has an overall rating of signal_hold, with a price target of 2.50.
What is the Earnings Per Share (EPS TTM) of Pliant Therapeutics Inc (PLRX)?
The Earnings Per Share (EPS TTM) of Pliant Therapeutics Inc (PLRX) is -2.43.